Galectin Therapeutics Inc. Common Stock (GALT)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at Galectin through a Graham lens and see a speculative clinical-stage enterprise, not a proven business. It has no revenue in the filed periods, and it lost $30.8 million in FY2025, $47.0 million in FY2024, and $41.1 million in FY2023. In fiscal Q2 2026, the quarter ended 2026-06-30, the net loss was $9.1 million, or $0.14 per diluted share, wider than the $7.5 million loss in fiscal Q2 2025. Trailing free cash flow is -$15.9 million, a -4.3% FCF yield on a $372.1 million market cap at the 2026-10-13 close. That means shareholders are funding a promise, not a cash-generating concern. The only asset that matters is belapectin, in Phase 2 and Phase 2b studies in MASH with advanced fibrosis and compensated cirrhosis with portal hypertension. An economic moat is not visible: no sales, no profits, and just 9 employees. Financial health scores are alarming: Altman Z-Score -51.80 and Piotroski F-Score 0/9. The FairStock P/E at that close is -8.39 and ROCE is -64.18%, both reflecting losses. There was some improvement from FY2024 to FY2025 as the net loss narrowed, but the recent quarter shows the burn continues. With no dividend and negative FCF, future capital raises are likely unless a partner funds development. At $3.69, the price embeds substantial clinical hope. Graham would demand a margin of safety; here the margin rests on binary trial outcomes, not on assets or earnings. I can admire the science but cannot call this a durable business on these figures.

In plain English: Galectin is a small drug developer working on treatments for fibrotic disease and cancer, mainly with a drug called belapectin. It has no sales yet and has lost money in each recent year, so the business looks weak on current results. At $3.69 a share, the price looks expensive compared with today's numbers because profits and cash flow are negative; the value mostly depends on future trial results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer